To further corroborate the association of SUMOylation and the DDR, we classified DLBCL patients into SUMOhigh and SUMOlow based on transcriptome profiles and performed GSEA based on expression of the SUMO core machinery (Demel et al, 2022) genes UBE2I, SAE1, SAE2, SUMO1, SUMO2 and SUMO3 (Fig 6A). The gene discussed is SUMO3; the disease is diffuse large B-cell lymphoma.